Diabetes Risk Allele of Transcription Factor 7-like 2 (TCF7L2) Polymorphisms is Associated with Higher Glucagon-like Peptide 1 (GLP1) and Lower Insulin Secretion
Abstract
BACKGROUND: The most influential susceptible gene associated with diabetes, transcription factor 7-like 2 (TCF7L2), has been observed in diverse populations. TCF7L2 influences type 2 diabetes risk through glucagon-like peptide 1 (GLP1) production. The presence of risk allele of TCF7L2 leads to the alteration of gene expression in pancreatic beta cells; however, how the mechanism is related with GLP1 remains unclear. This study was conducted to explore the variations of GLP1 increment and insulin secretion between individuals with and without diabetes risk allele of single nucleotide polymorphisms (SNPs) in TCF7L2.
METHODS: A cross-sectional analytic study was conducted involving individuals subjects who harbored known variants of SNPs in the TCF7L2: heterozygote or mutant of rs12255372 (GT or TT), rs7903146 (CT or TT), rs10885406 (AG or GG); as well as control subjects with wild type of rs12255372 (GG), rs7903146 (CC), and rs10885406 (AA). Anthropometric parameters, blood glucose, insulin, and GLP1 were measured; and homeostasis model assessment-beta cell (HOMA-%B) index was calculated.
RESULTS: The GLP1 increment response was higher in subjects carrying the diabetes risk allele (0.34±0.80 ng/mL) than those with the wild type (-0.04±0.57 ng/mL) (p=0.041). The HOMA-%B was reduced in subjects carrying the diabetes risk allele (71.64±24.72) than those with the wild type (103.23±68.00) (p=0.011). Among individuals carrying the diabetes risk allele, the likelihood of GLP1 increment with high response was twice as high (p=0.007), while the occurrence of low HOMA-%B was 1.47 more frequent (p=0.011).
CONCLUSION: TCF7L2 polymorphisms were associated with the GLP1 increment response and reduced HOMA-%B, which might be potentially contributing to GLP1 resistance in patients with diabetes risk factors.
KEYWORDS: diabetes risk, TCF7L2, GLP1, HOMA-%B
Full Text:
PDFReferences
Gloyn AL, Braun M, Rorsman P. Type 2 diabetes susceptibility gene TCF7L2 and its role in β-cell function. Diabetes. 2009; 58(4): 800-2, CrossRef.
Kartika R, Wibowo H. Impaired function of regulatory T cells in type 2 diabetes mellitus. Mol Cell Biomed Sci. 2020; 4(1): 1-9, CrossRef.
Grant SF, Thorleifsson G, Reynisdottir I, Benediktsson R, Manolescu A, Sainz J, et al. Variant of transcription factor 7-like 2 (TCF7L2) gene confers risk of type 2 diabetes. Nat Genet. 2006; 38(3): 320-3, CrossRef.
Zhang C, Qi L, Hunter DJ, Meigs JB, Manson JE, van Dam RM, et al. Brief genetics report: Variant of transcription factor 7-like 2 (TCF7L2) gene and the risk of type 2 diabetes in large cohorts of U.S. women and den. Diabetes. 2006; 55(9): 2645-8, CrossRef.
Goodarzi MO, Rotter JI. Testing the gene or testing a variant? The case of TCF7L2. Diabetes. 2007; 56(10): 2417-9, CrossRef.
Helgason A, Palsson S, Thorleifsson G, Grant SF, Emilsson V, Gunnarsdottir S, et al. Refining the impact of TCF7L2 gene variants on type 2 diabetes and adaptive evolution. Nat Genet. 2007; 39(2): 218-25, CrossRef.
Sladek R, Rocheleau G, Rung J, Dina C, Shen L, Serre D, et al. A genome-wide association study identifies novel risk loci for type 2 diabetes. Nature. 2007; 445(7130): 881-5, CrossRef.
Van Vliet-Ostaptchouk JV, Shiri-Sverdlov R, Zhernakova A, Strengman E, van Haeften TW, Hofker MH, et al. Association of variants of transcription factor 7-like 2 (TCF7L2) with susceptibility to type 2 diabetes in the Dutch Breda Cohort. Diabetologia. 2007; 50(1): 59-62, CrossRef.
Meigs JB, Manning AK, Fox CS, Florez JC, Liu C, Cupples LA, et al. Genome-wide association with diabetes-related traits in the Framingham Heart Study. BMC Med Genetics. 2007; 8(Suppl 1): S16, CrossRef.
Lyssenko V, Jonsson A, Almgren P, Pulizzi N, Isomaa B, Tuomi T, et al. Clinical risk factors, DNA variants, and the development of type 2 diabetes. N Engl J Med. 2008; 359(21): 2220-32, CrossRef.
Amoli MM, Amiri P, Tavakkoly-Bazzaz J, Charmchi E, Hafeziyeh J, Keramatipour M, et al. Replication of TCF7L2 rs7903146 association with type 2 diabetes in an Iranian population. Genet Mol Biol. 2010; 33(3): 449-51, CrossRef.
Danquah I, Othmer T, Frank LK, Bedu-Addo G, Schulze MB, Mockenhaupt FP. The TCF7L2 rs7903146 (T) allele is associated with type 2 diabetes in urban Ghana: A hospital-based case-control study. BMC Med Genet. 2013: 14: 96, CrossRef.
Chang YC, Chang TJ, Jiang YD, Kuo SS, Lee KC, Chiu KC, et al. Association study of the genetic polymorphisms of the transcription factor 7-like 2 (TCF7L2) gene and type 2 diabetes in the Chinese population. Diabetes. 2007; 56(10): 2631-7, CrossRef.
Ng MC, Tam CH, Lam VK, So WY, Ma RC, Chan JC. Replication and identification of novel variants at TCF7L2 associated with type 2 diabetes in Hong Kong Chinese. J Clin Endocrinol Metab. 2007; 92(9): 3733-7, CrossRef.
Chandak GR, Janipalli CS, Bhaskar S, Kulkarni SR, Mohankrishna P, Hattersley AT, et al. Common variants in the TCF7L2 gene are strongly associated with type 2 diabetes mellitus in the Indian population. Diabetologia. 2007; 50(1): 63-7, CrossRef.
Hayashi T, Iwamoto Y, Kaku K, Hirose H, Maeda S. Replication study for the association of TCF7L2 with susceptibility to type 2 diabetes in a Japanese population. Diabetologia. 2007; 50(5): 980-4, CrossRef.
Horikoshi M, Hara K, Ito C, Nagai R, Froguel P, Kadowaki T. A Genetic Variation of the Transcription Factor 7-like 2 Gene is Associated with Risk of Type 2 Diabetes in the Japanese Population. Diabetologia. 2007; 50(4): 747-51, CrossRef.
Saraswati MR, Suastika K, Sudoyo H, Malik SG. Association of TCF7L2 polymorphisms with diabetes, lipid, and obesity in Balinese population. Indones J Biomed Sci. 2017; 11(2): 6-10, CrossRef.
Del Bosque-Plata L, Martínez-Martínez E, Espinoza-Camacho MÁ, Gragnoli C. The role of TCF7L2 in type 2 diabetes. Diabetes. 2021; 70(6): 1220-8, CrossRef.
Yi F, Brubaker PL, Jin T. TCF-4 mediates cell type-specific regulation of proglucagon gene expression by beta-catenin and glycogen synthase kinase-3beta. J Biol Chem. 2005; 280(2):1457-64, CrossRef.
Florez JC, Jablonski KA, Bayley N, Pollin TI, de Bakker PI, Shuldiner AR, et al. Diabetes prevention program research group. TCF7L2 polymorphisms and progression to diabetes in the Diabetes Prevention Program. N Engl J Med. 2006; 355(3): 241-50, CrossRef.
Saxena R, Gianniny L, Burtt NP, Lyssenko V, Giuducci C, Sjögren M, et al. Common single nucleotide polymorphisms in TCF7L2 are reproducibly associated with type 2 diabetes and reduce the insulin response to glucose in nondiabetic individuals. Diabetes. 2006; 55(10): 2890-5, CrossRef.
Lyssenko V, Lupi R, Marchetti P, Del Guerra S, Orho-Melander M, Almgren P, et al. Mechanisms by which common variants in the TCF7L2 gene increase risk of type 2 diabetes. J Clin Invest. 2007; 117(8): 2155-63, CrossRef.
Nauck MA, Quast DR, Wefers J, Pfeiffer AFH. The evolving story of incretins (GIP and GLP-1) in metabolic and cardiovascular disease: A pathophysiological update. Diabetes Obes Metab. 2021; 23(Suppl 3): 5-29, CrossRef.
Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: Insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985; 28(7): 412-9, CrossRef.
Wallace TM, Levy JC, Matthews DR. Use and abuse of HOMA modelling. Diabetes Care. 2004; 27(6): 1487-95, CrossRef.
Diabetes Trial Units [Internet]. HOMA calculator. The Oxford Centre for Diabetes, Endocrinology and Metabolims, University of Oxford [update 2015 Jan 2; cited 2015 Jan 27]. Available from: www.dtu.ox.ac.uk.
Malik SG, Saraswati MR, Suastika K, Trimarsanto H, Oktavianthi S, Sudoyo H. Association of beta3-adrenergic receptor (ADRB3) Trp64Arg gene polymorphism with obesity and metabolic syndrome in the Balinese: a pilot study. BMC Res Notes. 2011; 4: 167, CrossRef.
Marquezine GF, Pereira AC, Sousa AGP, J G Mill, W A Hueb, J E Krieger. TCF7L2 variant genotypes and type 2 diabetes risk in Brazil: significant association, but not a significant tool for risk stratification in the general population. BMC Med Genet 2008; 9: 106, CrossRef.
Oktavianthi S, Saraswati MR, Suastika K, Dwipayana P, Sulfianti A, Hayati RF, et al. Transcription factor 7-like 2 single nucleotide polymorphisms are associated with lipid profile in the Balinese. Mol Biol Rep. 2018; 45(5): 1135-43, CrossRef.
World Health Organization [Internet]. Regional Office for the Western Pacific. 2000. The Asia-Pacific perspective : redefining obesity and its treatment treatment. Sydney: Health Communications Australia. [cited 2024 Jun 1]. Available from: iris.who.int.
Altemimi MT, Musa AK, Mansour AA. The performance of glycated hemoglobin vs. oral glucose tolerance test in the diagnosis of glycemic disorders among women with polycystic ovary syndrome in Southern Iraq. Indones Biomed J. 2021; 13(2): 178-85, CrossRef.
Yabe D, Kuroe A, Lee S, Watanabe K, Hyo T, Hishizawa M, et al. Little enhancement of meal-induced glucagon-like peptide 1 secretion in Japanese: Comparison of type 2 diabetes patients and healthy controls. J Diabetes Invest. 2010; 1(1-2): 56-9, CrossRef.
Lastya A, Saraswati MR, Suastika K. The low level of glucagon-like peptide-1 (GLP1) is a risk factor of type 2 diabetes mellitus. BMC Res Notes. 2014; 7: 849, CrossRef.
Putera BW, Sartika CR, Wijaya A. The dynamic roles of visfatin and obestatin serum concentration in pancreatic beta cells dysfunction (HOMA-B) and insulin resistance (HOMA-IR) in centrally obese Men. Indones Biomed J. 2012; 4(1): 43-9, CrossRef.
Tursinawati Y, Kartikadewi A, Yuniastuti A, Susanti R. Association of rs10830963 MTNR1B and rs841853 SLC2A1 polymorphism with obesity on type 2 diabetes patients: An overview of melatonin receptor and transporter. Indones Biomed J. 2021; 13(2): 106-220, CrossRef.
DOI: https://doi.org/10.18585/inabj.v16i5.3202
Copyright (c) 2024 The Prodia Education and Research Institute
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Indexed by:
The Prodia Education and Research Institute
